7. Bristol-Myers Squibb

Total: $222.4 million
TV: $152.2 million
Magazine: $61.5 million
Newspaper: $8.5 million
Radio: $22,200

For Bristol-Myers Squibb ($BMY), there is a rising star and a setting sun. Still on the rise--and on a potential blockbuster course--is next generation blood thinner Eliquis, which it co-markets with Pfizer ($PFE). But as of April 28, the antipsychotic Abilify, which BMS markets along with partner Otsuka, faces a cadre of generic competitors.

Overall ad spending was up for BMS last year, by 42% over 2014. Overall revenue, however, was down to $15.9 billion from $16.4 billion in 2013. While 2015 sales look to be another trough, Bristol-Myers' immunotherapy cancer drug Opdivo is predicted by analysts to make, and possibly break, a $6 billion peak in sales. That probably doesn't mean a big impact on ad spending, however, as oncology drugs are generally not targeted at mass audiences.

For more:
Bristol-Myers is counting on DTC to keep driving Eliquis growth
BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt
The PD-1 wave? Report says it's a $33B tsunami, with BMS surfing for first place
With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck's Keytruda

7. Bristol-Myers Squibb
Read more on

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?